News Cladribine Tablets Reduce Brain Atrophy in MS Patients, Merck Study Finds Cladribine Tablets Reduce Brain Atrophy in MS Patients, Merck Study Finds by Patricia Silva, PhD | February 14, 2017 Share this article: Share article via email Copy article link EMD SorenoĀ has recently published Phase 3 clinical data showing that CladribineĀ tablets reduced the annualized rate of brain volume loss (BVL, brain atrophy) compared toĀ placebo in patients with relapsing-remitting multiple sclerosis (RRMS). The study, āReduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets,ā which appearedĀ in the Multiple Sclerosis Journal, reports the results of a post hoc analysis of the Phase 3 CLARITY study. CLARITY was a randomized, double-blind, three-arm, placebo-controlled, multi-center Phase 3 clinical trial (NCT00213135) that evaluated the safety and efficacy of oralĀ CladribineĀ in 1,326 RRMS patients. The primary endpoint was the assessment of the annualized rate of relapse (ARR) at 96 weeks, and key secondary endpoints included the number of relapse-free patients and the sustained progression of disability. In a study previously published in The New England Journal of Medicine, EMD Soreno ā the biopharmaceutical arm ofĀ MerckĀ KGaA āĀ reported that all endpoints were met. Cladribine treatmentĀ significantly reduced ARR, the risk of disability progression and MRI measures of disease activity at 96 weeks. In the new study, the companyĀ reported data after two years ofĀ Cladribine treatment in short-duration courses.Ā Brain atrophy analysis assessed the effectiveness of Cladribine tablets on BVL and the association of BVL with disability progression in 1,025 relapsing MS (RMS) patients from the CLARITY study. Results revealed that, compared with placebo, the mean percentage of BVL per year was significantly lowerĀ in patients treated with Cladribine tablets 3.5āmg/kg and 5.25āmg/kg (ā0.70% vs. ā0.56% andĀ ā0.57%, respectively).Ā The risk of disability progression was also lower in treated patients treated compared to placebo. Patients with lower rates of brain atrophy were also likely to remain free ofĀ disability progression. In September 2016, EMD SorenoĀ reported dataĀ from the two-yearĀ CLARITY EXTENSION (NCT00641537) trial, in which RMS patients in the original trial’s placebo arm wereĀ switched to Cladribine treatment. Results demonstrated that these patientsĀ had significantly reduced ARR and were more likely to be relapse-free at the end of the extension phase. ARR was also maintained in patients who had received Cladribine tablets during the CLARITY trial and movedĀ to placebo for the extension study. “Evidence shows that brain atrophy in general accumulates throughout the course of multiple sclerosis and is associated with disability progression. This analysis is important because it confirms the link between reduced brain atrophy and reduced disability progression found in the CLARITY study,” Nicola De Stefano, the publication’s lead author and an associate professor of neurology at Italy’s University of Siena, said in a press release. “These findings reinforce and expand on the consistent and positive effect of Cladribine tablets in improving clinically relevant outcomes, such as reducing relapse rate and disability, and further our resolve to make this investigational therapy available for patients living with RRMS,” saidĀ Steven Hildemann, MD, PhD, Merck’s global chief medical officer and head of global medical affairs and safety. Cladribine is an oral small molecule that selectively and periodically targets immune lymphocytes, which are believedĀ to have aĀ central roleĀ in the processes that advance MS. Cladribine was also evaluated in the ORACLE-MS study (NCT00725985), with results showing that patients with a first demyelinating event who were given Cladribine tablets saw theirĀ risk of disease progression to clinically definite MS significantly reducedĀ compared to placebo. Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags brain volume loss, Cladribine, CLARITY, disability, disease progression, Merck, relapse, RRMS
April 23, 2024 News by Margarida Maia, PhD AAN 2024: Subcutaneous Ocrevus led to nearly no relapses after year
April 22, 2024 News by Margarida Maia, PhD Viatris launches low-dose Copaxone generic formulation in Canada
April 22, 2024 News by Marisa Wexler, MS AAN 2024: Briumvi found to ease disability in certain MS patients